MedTrace Logo

Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

NCT00693056 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-05-05

No results posted yet for this study

Summary

The primary objective of this Phase IIa trial is to determine the effective doses and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ED receiving RX-10100 treatment.

Conditions

  • Erectile Dysfunction (ED)

Interventions

DRUG

Placebo

Placebo (w/o API)

DRUG

RX-10100 5mg

5 mg/dose of RX-10100

DRUG

RX-10100 10mg

10 mg/dose of RX-10100

DRUG

RX-10100 15mg

15 mg/dose of RX-10100

Sponsors & Collaborators

  • Rexahn Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Hyungjoo Hugh Lee, MS · Rexahn Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-03-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693056 on ClinicalTrials.gov